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Abstract
Background: To date very few systems have been described for preclinical investigations of human cellular
therapeutics in vivo. However, the ability to carry out comparisons of new cellular vaccines in vivo would be of
substantial interest for design of clinical studies. Here we describe a humanized mouse model to assess the efficacy
of various human dendritic cell (DC) preparations. Two reconstitution regimes of NOD/scid IL2Rg
null (NSG) mice
with adult human peripheral blood mononuclear cells (PBMC) were evaluated for engraftment using 4-week and 9-
week schedules. This led to selection of a simple and rapid protocol for engraftment and vaccine evaluation that
encompassed 4 weeks.
Methods: NSG recipients of human PBMC were engrafted over 14 days and then vaccinated twice with
autologous DC via intravenous injection. Three DC vaccine formulations were compared that varied generation
time in vitro (3 days versus 7 days) and signals for maturation (with or without Toll-like receptor (TLR)3 and TLR7/8
agonists) using MART-1 as a surrogate antigen, by electroporating mature DC with in vitro transcribed RNA
encoding full length protein. After two weekly vaccinations, the splenocyte populations containing human
lymphocytes were recovered 7 days later and assessed for MART-1-specific immune responses using MHC-
multimer-binding assays and functional assessment of specific killing of melanoma tumor cell lines.
Results: Human monocyte-derived DC generated in vitro in 3 days induced better MART-1-specific immune
responses in the autologous donor T cells present in the humanized NSG mice. Moreover, consistent with our in
vitro observations, vaccination using mature DC activated with TLR3 and TLR7/8 agonists resulted in enhanced
immune responses in vivo. These findings led to a ranking of the DC vaccine effects in vivo that reflected the
hierarchy previously found for these mature DC variations in vitro.
Conclusions: This humanized mouse model system enables comparisons among different DC vaccine types to be
rapidly assessed in vivo. In addition, ex vivo analyses of human CD3
+ T cells recovered from the spleens of these
mice are also possible, including studies on lymphocyte subsets, Th1/Th2 polarization, presence of regulatory T
cells and the impact of DC vaccination on their functions.
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Dendritic cell (DC) vaccines hold high therapeutic
potential for induction of antitumor immunity in cancer
patients [1,2]. Many current cancer vaccines focus on
mature DC (mDC) loaded with tumor-associated anti-
gens (TAA) and injected intradermally to activate CD8
+
cytotoxic T lymphocytes (CTL). Monocyte-derived DC
are commonly used in DC vaccine strategies.
Various methods have been developed for preparation
of monocyte-derived mDC for clinical studies. These
mostly rely on a 6-day protocol using IL-4 and GM-CSF
to induce immature DC (iDC), followed by a 24 h
maturation phase [3]. Published studies demonstrated
that monocyte-derived DC generated over 2 or 3 days
give comparable [4] or enhanced [5] immune responses
in vitro compared to 7-day mDC. Many clinical trials
have utilized a four-component cocktail (4C) containing
IL-1b,I L - 6 ,T N F - a and PGE2 for DC maturation [6].
The discovery that TLR agonists can optimally activate
murine DC to secrete IL-12 [7] led to studies of the
impact of TLR agonists on human mDC cytokine pro-
duction [8-14]. Encouraging results have also been
obtained in the first clinical trial using TLR-stimulated
DC [15] as well as studies using TLR agonists as
immune stimulatory adjuvants [16]. We also have
described DC maturation cocktails using quinoline-like
molecules, R848 or CL075, in 3-day and 7-day mDC
[17,18]. In vitro studies of DC matured with TLR7/8
agonists, with or without poly (I:C) as a TLR3 agonist,
resulted in substantial secretion of bioactive IL-12(p70)
and high potential to activate innate and adaptive
immune responses [17,18].
Humanized mouse models could provide a useful pre-
clinical tool for assessment of immune responses in vivo
[19] but reports characterizing immune responses after
DC-based vaccination are rare [20,21]. Engraftment of
human peripheral blood lymphocytes (PBL) in mice has
been reported using two NOD/scid strains, one with a
truncated mutation (NOG) and one with a null muta-
tion (NSG) of the IL-2-receptor g-chain, using either
human CD34
+ stem cells or peripheral blood mononuc-
lear cells (PBMC) [22,23]. Our main interest was to
assess T cell responses using autologous DC-based vac-
cines. Humanized mice reconstituted with PBMC were
considered most amenable for such studies since they
enabled purified monocytes to be used for the genera-
tion of autologous mDC. Engraftment of PBMC places
constraints on the vaccination protocol due to the devel-
opment of confounding xenogenic responses over time.
These limitations can be bypassed using CD34
+ stem
cells for NSG reconstitution [24], but the acquisition of
CD34
+ cells, along with autologous monocytes for DC
generation, is more difficult.
To assess our model, we used NOD/scid IL2Rg
null
(NSG) mice to engraft human PBMC and performed
vaccination experiments using 3- and 7-day mDC pre-
pared in vitro from the same donors. Additionally, we
compared cocktail 4C with our maturation cocktail con-
t a i n i n gp o l y( I : C )a saT L R 3a g o n i s ta n dR 8 4 8a sa
TLR7/8 agonist (5C+R848). Our comparisons showed
that variably matured DC had different impacts on
induction of antigen-specific CD8
+ T cells in vivo, open-
ing the door to use this humanized mouse model to
assess variations in DC vaccines in vivo.
Methods
Preparation of PBMC for engraftment of NSG mice and in
vitro generation of mDC
Peripheral blood of healthy donors was prepared as
described [18]. In brief, fresh whole blood from healthy
adult donors collected with preservative free heparin
was diluted (1:3) with low endotoxin PBS (PBSle) (Bio-
chrom) and the leukocyte fraction was enriched using
standard ficoll gradient centrifugation. The interface was
harvested and washed twice with PBSle. Afterwards
PBMC were used directly for engraftment using intrave-
nous injection of cells in PBSle or as sources of mDC
[5,18]. For DC preparation, monocytes were isolated via
flask adhesion and cells were cultured for 2 or 6 days
with IL-4 and GM-CSF. Afterwards, maturation cock-
tails were added as described [18] using 4C and 5C
+R848 cocktails. See Table 1 for cytokine concentra-
tions. DC were harvested after 24 h, loaded with antigen
and incubated for an additional 6 h before injection into
mice reconstituted with human PBMC. Collection of
blood from healthy donors was approved by the “Ethics
Board of the Medical Faculty of the Ludwig-Maximi-
lians-University” Munich, Germany and donors gave
informed consent.
Surface phenotyping of mDC
Labeling of harvested mDC was performed with mono-
clonal antibodies against CD14 (FITC, clone MFP9),
CD80 (PE, clone L307.4), CD274 (B7-H1, FITC, clone
MIH1) (all BD Biosciences) and CD83 (PE, clone
Table 1 Composition of cocktails used for DC maturation
Cocktail Inflammatory cytokines/
interferons
Other
additives
TLR-
ligands
4C TNF-a, IL-1b, IL-6 PGE2
5C +
R848
TNF-a, IL-1b, IFN-g PGE2 poly(I:C),
R848
The following concentrations were used in the maturation cocktails:
4C :T N F - a (10 ng/ml); IL-1b (10 ng/ml); PGE2 (1000 ng/ml); IL-6 (15 ng/ml)
5 C + R848: TNF-a (10 ng/ml); IL-1b (10 ng/ml); PGE2 (250 ng/ml); IFN-g (5000
U/ml); poly (I:C) (20 ng/ml); R848 (1 μg/ml)
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cells were washed and analyzed using a FACSCalibur
instrument (BD Biosciences). Post-acquisition data was
analyzed using the FlowJo 8 Software (Tree Star, Ash-
land, OR).
Signal 3 assay of cytokine secretion
2×1 0
4 harvested and washed mDC were cocultured
with 5 × 10
4 CD40L-expressing murine fibroblasts as a
mimic for interaction with activated T cells, as described
previously [18]. Following 24 h-coculture, supernatants
were collected for detection of IL-10 and IL-12(p70).
Cytokine secretion measurement by ELISA
Collected supernatants of signal-3-assay cocultures were
analyzed for the amounts of secreted IL-10 and IL-12
(p70) using standard ELISA. The amount of human
IFN-g was also measured in serum samples of immu-
nized mice using standard ELISA kits (BD Systems)
according to manufacturer’s instructions. Colorimetric
substrate reaction with tetramethylbenzidine and H2O2
was stopped with H3PO4 and measured at 450 nm and
wavelength correction at 620 nm and analyzed with
“easy fit” software (SLT).
Engraftment PBMC in NSG mice
For the 9-week reconstitution protocol, mice were irra-
diated with a sub-lethal dose of 100cGy one day before
intravenous injection of 1 × 10
6 human PBMC, while
the 4-week protocol used a single intravenous injection
of 10 × 10
6 PBMC, without irradiation. Mice were vacci-
nated first on day 42 or day 14 after reconstitution,
respectively. The Bavarian State authorities approved all
animal experiments.
Electroporation of mDC and vaccination of humanized
mice
Specific antigen was introduced to mDC in the form of
in vitro-transcribed-RNA (ivt-RNA) encoding full length
protein, as described [5]. Electroporation of mDC was
performed using 48 μgo fivt-RNA, prepared from line-
arized T7-promotor-containing plasmid, with the
mMESSAGE mMACHINE T7 kit (Ambion), following
the manufacturer’s instructions. We used the plasmid
pcDNAI containing MART-1 cDNA. Electroporation
was performed as described in [5] and mDC were cul-
tured 6 h following electroporation. Afterwards, mDC
were injected immediately or cryopreserved for later
vaccination. DC (1 × 10
6) were given twice intrave-
nously, with a one-week interval between injections.
After 7-14 days, mice were sacrificed and splenic popu-
lations containing human lymphocytes prepared for in
vitro characterization of immune responses.
Functional analysis and flow cytometry
Splenic populations with human cells were also cultured
in RPMI 1640 medium supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1
mM non-essential amino acids and 5 μM beta mer-
captho-ethanol, over a 7-day period, in the presence of
50 IU/ml human IL-2 and 0.1 μg/ml OKT-3, prior to
chromium-release assays. Cytotoxic assays were per-
formed as described [18]. Tumor cell lines used as tar-
gets were cultured as described [18,25]. For flow
cytometry, splenic populations were cultured overnight
without supplementations of IL-2 and OKT-3 and
stained using an HLA-A2/MART-125-36-specific multi-
mer (peptide sequence: ELAGIGILT; PE-conjugated;
kindly provided by D. Busch, Technical University of
Munich) or with an HLA-A2/CMVpp65-specific control
multimer for 20 minutes, followed by washing and stain-
ing with specific CD3 (PerCP; clone SK7, BD) and CD8
(APC; clone SK1, BD) or with directly labeled CD3,
CD4 (PE; clone 13B8.2, Immunotech), CD8, CD62L
(FITC; clone SK11, BD) antibodies. Measurement was
performed using a LSRII machine and FlowJo software
for analyses. Staining of blood samples was performed
accordingly, including an erythrocyte lysis step prior to
staining with antibodies.
Results
Human PBMC rapidly engraft in NSG mice
To develop a humanized mouse model to study DC vac-
cination in vivo, we used NSG mice xenografted with
human PBMC. Initially we compared two published
engraftment methods, with minor modifications [20,26].
As shown in Figure 1A and 1B, the protocols differed in
the length of 9 weeks (9-wk) (Figure 1A) or 4 weeks (4-
wk) (Figure 1B). For the 9-wk protocol, mice were irra-
diated with a sub-lethal dose of 100 cGy, 24 h prior to
injection of 1 × 10
6 human PBMC. By contrast, the 4-
wk protocol utilized non-irradiated recipients which
received 10 × 10
6 PBMC.
Weekly analysis of CD3/CD45-positive cells in blood
withdrawals of non-vaccinated mice showed T cell
engraftment by both protocols (Figure 1C). At week
three, faster engraftment was seen using the 4-wk proto-
col. This was accompanied by a higher percentage of
CD62L-positive cells in the CD3/CD45-positive fraction,
indicated as italic numbers in the FACS plots. Both pro-
tocols showed comparable engraftment at week four.
DC vaccines differ in phenotype and IL-12 secretion
We have previously reported on the development of
monocyte-derived DC-based vaccines that use mature
cells produced in a shorter 3-day period instead of the
more standard 7-day culture duration [5]. In addition,
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TLR7/8 activation signals using synthetic agonists
[17,18]. Both modifications enhanced the capacity of
mDC to induce antigen-specific T cell responses in vitro
[5,17,18]. These variations were selected for assessment
in reconstituted mice. To monitor the in vitro matura-
tion process of DC for later administration to huma-
nized mice in vivo, we determined expression of the
markers CD14 and CD83 on human DC generated via
3-day or 7-day culture periods. Furthermore, 3-day DC
were compared after maturation with two different
cocktails (4 C or 5 C + R848). As reported previously,
all three mDC variants showed increased expression of
CD40, CD80, CD86, HLA-DR and CCR7 to varying
degrees (data not shown) [5,17,18]. The maturation sta-
tus of the three mDC variations was compared by deter-
mining percentages of CD83-positive cells. Significant
differences were not detected among the three variants
(Figure 2A). As a second parameter, we assessed the
amounts of IL-10 and IL-12(p70) secreted after T cell
encounter, mimicked in a signal-3-assay using CD40L-
expressing murine fibroblasts for DC stimulation. The
amounts of IL-12(p70) to IL-10 were compared by cal-
culating the ratio for each DC phenotype. These
confirmed published results that DC matured with 4C
failed to secret IL-12(p70). In contrast, the ratio of IL-
12(p70) to IL10 was significantly increased for 5C
+R848-matured, 3-day DC due to enhanced secretion of
IL-12(p70) [17,18] (Figure 2B). As a third feature, the
mDC were analyzed for their expression profile of the
positive costimulatory molecule CD80 compared to that
of the inhibitory costimulatory molecule CD274 (B7-
H1). As previously published, we observed changes in
the ratio of CD80 to CD274 between DC cultured for 3
days and 7 days, due to increased expression of CD274
over time [5]. Furthermore, we detected an additional
increase in the expression levels of CD80 when DC
were matured with 5C+R848 [18] (Figure 2C).
Taken together these results indicated that 5C+R848-
matured, 3-day mDC displayed an optimal phenotype
for the induction of antitumor immunity based on
assessments in vitro. Our functional studies in vitro also
supported this contention [5,17,18]
DC vaccination does not impact on engraftment
Because the engraftment protocols had substantial dif-
ferences with respect to time, numbers of PBMC and
irradiation of NSG recipients, it was important to
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Figure 1 Efficacy of engraftment of human PBMC in NSG mice.( A) Schema of 9-wk engraftment protocol. Mice were irradiated 24 h prior
to i.v. injection of 1 × 10
6 human PBMC and spleens were isolated on day 63. (B) Schema of 4-wk engraftment protocol starting with i.v.
injection of 10 × 10
6 human PBMC on day 1. Isolation of spleens was performed on day 28. (C) Representative staining of CD3 vs. CD45 in
blood withdrawals of individual mice engrafted with the 9-wk or the 4-wk protocol on week 2, 3 and 4. Italic numbers given beside the CD3/
CD45-positive population indicate the percentage of CD62L-positive cells within the double-positive fraction.
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mice were altered by vaccination. Further, we com-
pared the DC variants since different DC phenotypes
might impact directly on T cell engraftment. Mice
engrafted with the 9-wk protocol were first
immunized with the DC vaccines 6 weeks later (Figure
3A) while the first immunization was performed two
weeks following engraftment in the 4-wk protocol
(Figure 3B). Vaccination of mice in each group con-
sisted of two intravenous injections of 1 × 10
6 mDC,
separated by a one-week interval. Freshly prepared
mDC from autologous donors were used for the first
vaccination and cryopreserved mDC were used from
the same production lot for the second vaccination.
The characteristics described for the mDC (Figure 2)
were not altered by cryopreservation (data not shown)
[5].
FACS analysis of splenic cells of vaccinated mice
showed comparable engraftment of human CD3
+ T
cells, as illustrated for representative animals of each
protocol at the day of harvest (day 63 and day 28),
respectively (Figure 3C). The most prominent distinc-
tion noted in the mice was the higher numbers of CD4
+
and CD8
+ cells expressing CD62L, which is characteris-
tic of naïve lymphocytes, in the mice reconstituted by
the 4-wk protocol (Figure 3C). Mean percentages of
CD3
+ T cells were 56.3% and 64.5% for the 9-wk and 4-
wk groups, respectively (Figure 3D). As a group, mice
reconstituted with the 9-wk protocol had higher mean
percentages of CD8
+ T cells (57.8% vs. 48.9%), whereas
mice reconstituted with the 4-wk protocol showed
greater numbers of CD4
+ T cells (31.7% vs. 40.6%),
reflecting more the normal situation in humans. The
strong distinction noted in Figure 3C with respect to
CD62L expression was consistently reflected in the two
groups of mice (11.6% vs. 23.7%) (Figure 3D). This indi-
cates that at the time of analysis the majority of lympho-
cytes of the 9-wk group had been activated in vivo,
whereas a fraction of naïve cells remained in the 4-wk
group. It is important to note that differences were not
seen with the use of different vaccine variants, but
rather reflected differences in the engraftment protocol
as a whole.
Furthermore, we observed signs of graft-versus-host
disease (GvHD) approximately 5 weeks after engraft-
ment using the 9-wk protocol (not shown), which
resulted in untimely death of several mice. Mice showed
a strong loss of weight, fur loss and thin red skin, char-
acteristics previously described for a xenograft GvHD
model [27]. Additional analysis of the sera of sacrificed
mice demonstrated increased levels of IFN-g in mice
generated with the 9-wk protocol (range: 500-5000 pg/
ml) compared to sera of mice generated with the 4-wk
protocol (< 50 pg/ml) (Figure 3E). Based on these obser-
vations, we selected the 4-wk procedure for further DC
vaccination studies. Since the engraftment characteristics
of vaccinated mice were comparable to non-vaccinated
animals, it can be concluded that the DC as applied did
not impact on engraftment.
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Figure 2 Phenotypic and functional analysis of differently
matured DC.( A) Percent of CD83-positive cells measured on 7-day,
4C-matured DC (n = 6) as well as 3-day, 4C- and 5C+R848-matured
DC (n = 4). Percent of CD14-positive cells ranged between 0.9 and
5.7 percent in the tested populations. (B) Ratio of secreted IL-12
(p70) to IL-10 assessed by standard ELISA of signal-3-assay
supernatants. Analyzed DC were matured using the 7-day, 4C
protocol (n = 7) or the 3-day protocol in combination with 4C or
5C+R848 mediated maturation (n = 4). (C) Ratio of the mean
fluorescence intensity of CD80 to CD274 (B7-H1) assessed on 7-day,
4 C generated mDC (n = 3) as well as 3-day DC matured with 4C or
5C+R848 cocktails (n = 6). Significance was ascertained using a two-
tailed Mann-Whitney U test and p-values were defined as following:
** = p < 0.005; * = p < 0.05; n.s. = p > 0.05.
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Figure 3 Influence of vaccination on the engraftment efficacy of human PBMC.( A) Schema of 9-wk engraftment protocol in which
vaccination was performed using 1 × 10
6 mDC given on day 42 and day 49. Spleens were isolated on day 63. (B) Schema of 4-wk engraftment
protocol using injection of 1 × 10
6 mDC on day 14 and day 21. Spleens were isolated on day 28. (C) Representative examples for CD3 vs. SSC,
CD4 vs. CD62L and CD8 vs. CD62L (from left to right) of flow cytometry analysis comparing engraftment efficacy of 9-wk (left of each block) and
4-wk (right of each block) schemes. (D) Statistical analysis of engraftment efficacy comparing 9-wk and 4-wk protocols and mice vaccinated
using 7-day 4C-matured DC (circles), 3-day 4C-matured (squares) or 3-day 5C+R848-matured (triangles) DC; means are given in brackets.
Statistical analyses were performed using a two-tailed Mann-Whitney test and p < 0.05 were considered significant. Engraftment experiments
were performed at least 3 times with similar results. (E) Amounts of human IFN-g in sera of vaccinated mice engrafted with the 9-wk or 4-wk
protocol, respectively, were assessed using a standard ELISA. Depicted are means and SEM of 8 mice generated in two individual experiments.
The open square and open circle represent levels in individual non-vaccinated mice.
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immune response
To assess if antigen-specific T cell responses could be
detected in mice reconstituted and vaccinated with the
4-wk protocol, mDC were used for vaccination that
expressed the complete protein for the melanoma-asso-
ciated antigen MART-1. These mDC were prepared
from monocytes of an HLA-A2
+ donor that were elec-
troporated with ivt-RNA encoding full length MART-1
protein. NSG mice reconstituted with autologous HLA-
A2
+ PBMC were vaccinated twice as depicted in Figure
3B and seven days later splenic populations were ana-
l y s e db yF A C Su s i n gaM A R T - 1 - s p e c i f i cm u l t i m e rt o
enumerate CD8
+ multimer-binding cells within the
human CD3
+ T cell fractions. 7-day cultured mDC
usually failed to induce multimer-positive cells above
the background levels of non-vaccinated animals, while
3-day mDC derived using either 4 C or 5 C + R848
induced multimer-positive cells to varying degrees in
individual mice (Table 2). Examples of multimer-binding
to CD8
+ human lymphocytes present in isolated splenic
populations are shown in Figure 4A. Direct analysis of
these splenocyte populations ex vivo failed to demon-
strate detectable cytotoxic activity directed against HLA-
A2
+ MART-1
+ melanoma tumor cells as targets in a
standard chromium release assay (Figure 4B). It was also
not possible to measure secretion of interferon-gamma
(IFN-g) after coculture for 24 hours with these mela-
noma cells (Figure 4D).
Therefore, splenocytes from the vaccinated mice were
cultured for one-week in vitro in the presence of human
anti-CD3 antibody and human IL-2 to enrich the
human T cells before again assaying their cytotoxic
function. Enrichment efficacy was controlled on day 6 of
ex vivo culture and resulted in a purity of at least 80%
human CD3
+ T cells (data not shown). The subsequent
chromium-release assay assessed specific responses
using mel624.38 cells (HLA-A2
+,M A R T - 1
+) as positive
target cells and THP-1 cells (HLA-A2
+, MART-1
-)a n d
melA375 cells (HLA-A2
+,M A R T - 1
-) as negative con-
trols. As an additional control, K562 cells were used to
determine potential cytotoxic activity of human NK
cells. We did not observe specific lysis of any of these
three MART-1
- target cells in any of the tested samples
(data not shown). As indicated by the multimer-staining
results, human lymphocytes from mice immunized with
7-dayDC showed no clear lysis of tumor cells in vitro
(Figure 4C, *indicates mice depicted in Figure 4A). In
mice immunized with 3-day DC matured by 4C, human
lymphocytes of only one mouse of four in this experi-
ment showed strong specific lysis of the MART-1
+-cell
line, although splenic populations of three of the mice
were positive for multimer staining (Table 2). In con-
trast, 3-day DC matured with 5C+R848 induced MART-
1-specific responses in threeo ff o u rm i c e .T h es p e c i f i -
city of mel624.38 (HLA-A2
+, MART-1
+) killing was ver-
ified by demonstrating no recognition of melA375
(HLA-A2
+,M A R T - 1
-) melanoma cells (Figure 4E), nor
were THP-1 and K562 cells recognized as targets (data
not shown). The failure to measure any killing with
human CD3
+ T cells cultured from spleens of non-vac-
cinated animals served to demonstrate that the positive
responses detected in the two groups that were vacci-
nated with 3d-DC were not due to non-specific activa-
tion of MART-1-specific T cells through in vitro
culture, despite the absence of specific MART-1 antigen.
Collective results of chromium-release assays, per-
formed with cells cultured for 7 days after spleen isola-
tion, were evaluated for four independent reconstitution
experiments using the different MART-1-protein-
expressing mDC variants for vaccination of mice
engrafted with PBMC derived from HLA-A2
+ donors.
Specific cytotoxicity of the T cell cultures derived from
splenic populations of the three vaccination groups are
illustrated at an E:T of 40:1, analyzing the specific lysis
of mel624.38 cells as positive targets and THP-1 cells as
negative controls (Figure 5A). The highest specific lysis
was consistently observed with T cells from mice vacci-
nated with 3-day, 5C+R848 mDC, followed by 3-day, 4C
mDC. Little or no specific lysis was seen using cells
from mice vaccinated with 7-day, 4C DC, corresponding
with the negative results of multimer staining.
To account for variations in actual numbers of human
CD8
+ T cells among the lymphocytes cultured ex vivo,
we calculated a percentage relative lysis normalized to
the percentage of CD8
+ T cells in the individual cul-
tured splenic populations. Mean relative lysis at an E:T
of 20:1 for a total of 16 mice per group is given in Fig-
ure 5B. These results demonstrated that 3-day DC
matured with 5C+R848 were superior in their capacity
to induce human antigen-specific CD8
+ CTL.
We designated mice as responders if the in vitro cyto-
toxicity test showed a minimal specific lysis of 20% at
an E:T of 40:1. For mice vaccinated with 3-day, 5C
+R848-matured DC, we observed 75% responders (12 of
16 analyzed mice) (Figure 5C). Vaccination using 3-day,
4C-matured DC resulted in 44% responders (7 of 16
Table 2 Multimer-positive cells after vaccination with
MART-1-pulsed mature DC
mDC phenotype 7d-DC (4C) 3d-DC (4C) 3d-DC (5C+R848)
0.02 0.38 0.80
0.28 1.38 0.82
0.00 0.18 0.32
0.08 0.15
mean 0.10 0.51 0.52
SEM ± 0.09 ± 0.30 ± 0.17
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Figure 4 In vivo priming using DC-based vaccination.( A) MART-1-specific multimer staining versus CD8 staining of in vivo-primed human T
cells. Differently matured DC of an HLA-A2
+ donor, electroporated with MART-1 ivt-RNA, were used for vaccination. Staining was performed one
day after spleen isolation. (B) Killing capacity (% specific lysis) of human lymphocyte populations, shown in A, tested individually in a chromium-
release assay 24 h after isolation (ex vivo). 2 × 10
3 mel624.38 target cells were incubated with varying numbers of effector cells. Specific lysis of
non-immunized mice is shown as open circles while filled circles represent specific lysis of lymphocytes from immunized mice. THP-1 cells (HLA-
A2
+, MART-1
-) cells were not recognized (data not shown). (C) Killing capacity (% specific lysis) human lymphocyte populations cultured in vitro
after isolation from individual mice and tested separately in a chromium-release assay at day 7 after isolation. Responses of non-immunized mice
are shown as open circles while filled circles represent responses of immunized mice. Individual mice shown in (A) are indicated with * and the
analyzed lymphocyte populations correspond to the populations tested in B. THP-1 (HLA-A2
+, MART-1
-) and K562 (HLA-A2
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-) cells were
not recognized (data not shown). (D) Amount of secreted IFN-g by human lymphocyte populations after stimulation with mel624.38 cells
following in vitro culture for 7 days. Analysed cell populations correspond to those tested in B and C and were analysed on the same day as C.
Values are given as means of four mice with SEM and PMA/I stimulation served as the positive control. (E) Specific lysis of melA375 (HLA-A2
+,
MART-1
-) and mel624.38 (HLA-A2
+, MART-1
+) melanoma cell lines as target cells. Shown are means (SEM) of four mice vaccinated with MART-1-
expressing DC populations using the 4-wk protocol.
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13% responders (2 of 16 mice).
Discussion
While humanized mouse models have been efficiently
used to evaluate pathogen-directed vaccination strate-
gies, as nicely reviewed by Münz and colleagues [28],
few studies describe the use of humanized mice to
assess the efficacy of human DC vaccines [20,21]. The
ability to carry out in vivo comparisons of new DC vac-
cine approaches would be of substantial interest for
design of clinical trials.
We have developed a mouse model that is simple and
rapid based on the NSG mouse strain to investigate var-
ious human DC-based cellular therapeutics. By using
NSG mice that were engrafted with human PBMC
within two weeks, we successfully avoided the GvHD
reaction that was observed using a 9-wk engraftment
protocol, which became apparent in most mice as early
as week five post PBMC injection. Although engraft-
ment of human cord blood-derived stem cells would
result in reduced GvHD, the feasibility of obtaining
stem cells and DC from the same donor is very limited.
In addition, testing patient-derived DC with lympho-
c y t e so fh e a l t h yH L A - m a t c h e dd o n o r si sa l s od i f f i c u l t
due to limitations in finding suitable HLA matches. By
adapting a 4-wk protocol using 10 × 10
6 PBMC for
engraftment, followed by two vaccinations with 1 × 10
6
mDC, we were able to induce and detect allo-reactive
(data not shown) as well as autologous antigen-specific
responses in donor T cells from humanized NSG mice.
To test this NSG model, we compared three DC vac-
cine formulations that were previously characterized
extensively in vitro using MART-1 as an antigen. We
selected MART-1 for evaluation of antigen-specific
responses because of the known high frequency of CD8
+
T cells responding to this antigen in most healthy indi-
viduals, which can be detected easily with MHC-multi-
mers. In these studies, we did not analyze whether
MART-1-specific CD4
+ T cells were also present, but
the good reconstitution of human CD4
+ T cells in the
NSG mice generated using the 4-wk protocol may
indeed allow their induction through appropriate
vaccination.
The use of MART-1 as a surrogate antigen, like lym-
phocytic choriomeningitis virus (LCMV) and ovalbumin
(OVA) in many murine models, is suitable for many
comparisons. Further investigations will be required to
determine if responses to additional antigens can be
detected in vivo. Here it may be necessary to reconsti-
tute mice with PBMC of cancer patients to access
higher frequency memory responses to some TAA.
The DC populations that we compared in vivo varied
in time of generation (3d vs. 7d) and signals for matura-
tion (plus/minus TLR3, TLR7/8). In the humanized
mice, 7-day DC failed to induce potent immune
responses, while mDC generated in a 3-day period using
the 4C cocktail induced good responses in 44% of mice.
Furthermore, DC matured with the TLR3 and TLR7/8
agonists not only gave enhanced immune responses in
individual mice, but also increased the numbers of posi-
tive responders within the cohort to 75%. It is not
known whether failure to induce immune responses in
25% of mice is due to deficiencies in vaccination or
reflects variations among mice, for example, in qualita-
tive or quantitative levels of reconstitution. Nevertheless,
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Figure 5 In vivo priming efficiency of MART-1-positive DC.( A) Specific lysis of mel624.38 (HLA-A2
+, MART-1
+) and THP-1 (HLA-A2
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-)
target cells by splenic-derived human lymphocytes isolated from mice vaccinated with various mDC types. Depicted are means of results from
16 mice total per group generated in 4 individual experiments and tested for significance using a two-tailed Mann-Whitney test (p values were
considered as following * p < 0.05; ** p < 0.005; *** p < 0.0001) (B) Relative lysis of results shown in (A) adjusted for numbers of human CD8
+ T
cells. To account for individual experiments and mice, values were adjusted at an E:T of 20:1 as follows:% rel. specific lysis = % spec. lysis/(%
CD8/100). Given are means with SEM (* p < 0.05; ** p < 0.005; *** p < 0.0001, assessed by a two-tailed Mann-Whitney test). (C) Percentage of
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+ donor. Mice were considered as responders when human
lymphocytes, isolated and cultured from spleens, showed a specific lysis of HLA-A2
+, MART-1
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of 40:1. Analyzed were 4 individual experiments with a total of 16 mice in each group.
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to be drawn with respect to the three vaccine variations
analyzed here, which reflected the hierarchy we pre-
viously found in these mDC variations in vitro [5,17,18].
It was interesting to note that multimer-positive cells
were often detected in splenic populations after vaccina-
tion with 3-day 4C-matured DC, but parallel killing
capacity was not always detected in all in vitro cultures
of human CD3
+ T cells. Further studies of human cells
isolated directly from splenic populations may shed light
on this discrepancy. For example, it remains to be deter-
mined whether this represents anergy in some antigen-
specific T cells or perhaps an increased prevalence of
regulatory cells that suppress immune reactivity in vitro.
In the experiments reported here we used only intra-
venous injection of DC. Further studies will be required
to determine if subcutaneous or intradermal injection
will allow induction of immune responses. DC migration
to lymph nodes may not function well in NSG mice due
to the poor structure of their lymph nodes. The migra-
tory capacity of human mDC in a xenogenic tissue
microenvironment also remai n sa no p e nq u e s t i o nt h a t
will strongly impact on immune responses. Therefore, it
is fortunate that intravenous injection of mDC allowed
immune responses to be detected in human lympho-
cytes residing in the spleens of reconstituted mice. Stu-
dies regarding frequency of DC application and time
span of vaccination will be limited by the appearance of
xenoreactive cells, which were prominent already after
five weeks in mice reconstituted by the 9-wk protocol.
Conclusions
In conclusion, the NSG humanized mouse model system
described here enables investigation of therapeutic cell
reagents in an in vivo setting. This model easily allows
the assessment of the potential of various human DC
preparations to activate autologous antigen-specific T
cells in an in vivo setting if one uses PBMC from HLA-
A2
+ donors and MART-1 as a surrogate antigen. The
relatively small numbers of cells required for engraftment
and vaccination should allow some studies using patient
material. In particular, this model should enable compar-
isons among different DC vaccine types to be rapidly
assessed in vivo. Because the human CD3
+ T cells can be
recovered from the spleens of mice and cultured ex vivo,
further studies are applicable. For example these studies
could assess lymphocyte subsets, Th1/Th2 polarization,
as well as presence of regulatory populations and the
impact of DC vaccination on their functions.
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